| Literature DB >> 36076867 |
Wenwen Lv1,2,3,4,5,6, Duoxia Xu1,2,3,4,5,6.
Abstract
Docosahexaenoic acid (DHA), mainly found in microalgae and fish oil, is crucial for the growth and development of visual, neurological, and brain. In addition, DHA has been found to improve metabolic disorders associated with obesity and has anti-inflammatory, anti-obesity, and anti-adipogenesis effects. However, DHA applications in food are often limited due to its low water solubility, instability, and poor bioavailability. Therefore, delivery systems have been developed to enhance the remainder of DHA activity and increase DHA homeostasis and bioavailability. This review focused on the different DHA delivery systems and the in vitro and in vivo digestive characteristics. The research progress on cardiovascular diseases, diabetes, visual, neurological/brain, anti-obesity, anti-inflammatory, food applications, future trends, and the development potential of DHA delivery systems were also reviewed. DHA delivery systems could overcome the instability of DHA in gastrointestinal digestion, improve the bioavailability of DHA, and better play the role of its functionality.Entities:
Keywords: DHA delivery systems; anti-obesity; bioavailability; digestion; food applications
Year: 2022 PMID: 36076867 PMCID: PMC9455885 DOI: 10.3390/foods11172685
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1DHA molecular structure.
Figure 2Depiction of different delivery systems indicating the possible location of DHA.
Summary of DHA delivery systems.
| DHA Delivery System | Materials | Size | Encapsulation Efficiency | Storage Stability | Main Factors Affecting Stability | Reference |
|---|---|---|---|---|---|---|
| Microemulsions | Tween 80, CaCl2, surfactin | 15–50 nm | N/A | Stable for 2 years at 4 °C | Surfactant | [ |
| Nanoemulsions | Tween-40 | 10–30 nm | N/A | Stable over 100 days at 4 °C | Preparation technology | [ |
| Coffee oil, algae oil, Span 80, Tween 80, water | 30 nm | 100% | Emulsions were stable when heated up to 110 °C at a pH 6 | N/A | [ | |
| Multilayered emulsions | Lecithin, chitosan, maltodextrin | N/A | N/A | Stable for 12 days at 30 °C and 60 °C | The composition of the emulsions | [ |
| Liposomes | L-α-Phosphatidylcholine | 129.6 ± 0.4 nm | 70.3 ± 1.0% | N/A | N/A | [ |
| Pickering emulsions | Water, gelatin | 2.11–34.68 μm | N/A | Stable for 3 days at 4 °C, room temperature, 37 °C | Solution pH, homogenizing time, homogenizing speed, storage temperature | [ |
| Nanoparticles | PLGA, chitosan | 145–341 nm | 80.45% | Stable for 42 days at 30–80 °C | Materials | [ |
| Zein and PLGA | 319.9 ± 8.28 nm | 84.6% | Stable over 35 days at 4 °C | Materials | [ | |
| Microcapsules | Casein, glucose, lactose | 14.173 μm | 98.66% | Stable for 8 weeks at 45 °C | Wall materials | [ |
| Dodecenyl succinic anhydride-esterified agarose | 100–400 μm | 65–85% | Stable for 30 days at room temperature | N/A | [ | |
| Gels | Water, gelatin | 1.81 ± 0.02 mm | N/A | Stable length of study | Forms | [ |
Figure 3In vitro and in vivo digestion model of DHA delivery systems.
Figure 4Static digestion (A), semi-dynamic digestion (B), and dynamic digestion (C) models of DHA delivery systems.
Figure 5Functionality of DHA in delivery systems.
Functionality of DHA in delivery systems.
| Functionality | DHA Delivery System | Results | Reference |
|---|---|---|---|
| Improve cardiovascular diseases | Microemulsions | Increased DHA bioavailability by 77% and 41% in the heart and brain lipids | [ |
| Improve visual and neurological/brain development | Nanoparticles | Enhanced the DHA content in the brain | [ |
| Microcapsules | Increased DHA levels in blood | [ | |
| Improve diabetes mellitus | Microemulsions | Increased the absorption of DHA, which could reduce oxidative stress induced by high blood glucose | [ |
| Anti-obesity | DHA-PC | Reduced liver weight and hepatic triglyceride levels in OLETF rats to reduce obesity-induced fatty liver | [ |
| Anti-inflammation | DHA | Changed the secretion of adipokine in 3T3-L1 cells and had an anti-inflammatory effect | [ |
| DHA | Decreased TNF-α, IL-1β in LPS-induced inflammation and mediated anti-inflammatory effects through the NF-κB signaling pathway | [ | |
| DHA | Enhanced anti-inflammatory IL-10 secretion and significantly inhibited the expression of IL-6, IL-1β, TNF-α in macrophages | [ |
Figure 6Food applications of DHA delivery systems.